Peregrine Pharmaceuticals of Tustin, CA, has received a $464,000 grant from Philip Morris’ external research program to evaluate Peregrine’s tumor necrosis therapy (TNT) technology for lung cancer immunotherapy applications. The research will focus on using TNT to deliver various cytokines and chemokines to human lung cancer tumors, and will be directed by Dr. Alan Epstein, Ph.D from the University of Southern California’s Keck School of Medicine.
The research will also focus on identifying how the human body responds to this immunotherapy by observing and measuring various lymphocyte subpopulations activated by the therapy. Experiments will also be conducted to determine the effects of immunotherapy administered in combination with the deletion of various lymphocyte subpopulations, Peregrine said.
By AuntMinnie.com staff writers
September 9, 2003
TNT gets clearance in China, August 13, 2003
Peregrine, Affitech team up, June 18, 2003
Peregrine regains Nasdaq compliance, June 12, 2003
Peregrine, Schering team up, January 7, 2003
Peregrine begins Nasdaq grace period, August 22, 2002
Copyright © 2003 AuntMinnie.com